CARDIO-PULSE: CARDIOvascular disease and Chronic Obstructive PULmonary DiseaSE: a real-world observational study in Australian primary care

Study identification

• EU PAS number:
  EUPAS1000000940
• Study ID:
  1000000940
• Official title and acronym:
  CARDIO-PULSE: CARDIOvascular disease and Chronic Obstructive PULmonary DiseaSE: a real-world observational study in Australian primary care
• DARWIN EU® study:
  No
• Study countries:
  Australia
• Study description:
  The study will be an observational cohort study using data from Australian primary care electronic medical records from the Optimum Patient Care Research Database Australia (OPCRDA) The OPCRDA is a real-world, longitudinal, research database that is maintained by Optimum Patient Care Australia (OPCA). It contains anonymised health data from over one million patients from primary care across Australia.; ; The population will comprise adults aged ≥40 years with COPD, defined as a documented diagnosis of COPD and a prescription for COPD medication in the previous 2 years, who are clinically active (prescription and/or consultation data) on the OPCRDA database from 1 January 2021.The study will have 2 study aims.; ; For the first study aim, people with COPD will be matched by age/gender/smoking status to a cohort of individuals without COPD. Individuals will be followed up from 1 January 2021 for 3–5 years and incidence of new-onset cardiovascular disease (CVD) events, CVD risk score assessments and absolute risk scores will be compared and the predictors of future CVD events in high-risk COPD will be explored.; ; For the second study aim, the cohort will be restricted to individuals who are at high risk (i.e. have ≥2 exacerbations in the previous 24 months) and have at least one exacerbation within the follow-up period. The first exacerbation will be taken as the index date. People with pre-existing CVD (defined as stroke, myocardial infarction, angina, peripheral arterial disease, atrial fibrillation, and/or heart failure) will be compared to those without CVD in relation to time to COPD maintenance therapy change and incidence of new-onset CVD.
• Study status:
  Planned

Research institutions and networks

Institutions

Optimum Patient Care Australia

Australia

Observational and Pragmatic Research Institute (OPRI)

Networks

Optimum Patient Care (OPC) Network

United Kingdom (Northern Ireland)

Study timelines

Date when funding contract was signed

Planned:28/10/2026

Study start date

Planned:01/11/2026

Date of final study report

Planned:31/07/2026

Sources of funding

Other

More details on funding

Funding for this study was partially provided by OPCA and AstraZeneca

Regulatory

• Was the study required by a regulatory body?:
  Unknown
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable